Zacks Investment Research cut shares of Aytu Bioscience (NASDAQ:AYTU) from a buy rating to a hold rating in a report issued on Monday.
According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. “
Separately, Northland Securities set a $10.00 target price on Aytu Bioscience and gave the stock a buy rating in a research report on Tuesday, March 19th.
AYTU opened at $1.73 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.37 and a current ratio of 4.72. Aytu Bioscience has a 1 year low of $0.68 and a 1 year high of $13.40.
Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, February 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.37). The company had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.58 million. Aytu Bioscience had a negative return on equity of 95.52% and a negative net margin of 217.45%. As a group, equities research analysts anticipate that Aytu Bioscience will post -2.39 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Aytu Bioscience stock. Geode Capital Management LLC bought a new position in Aytu Bioscience Inc (NASDAQ:AYTU) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 54,580 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.44% of Aytu Bioscience as of its most recent filing with the SEC. 8.52% of the stock is currently owned by institutional investors.
About Aytu Bioscience
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Recommended Story: Buy-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.